<1xbet 후기ad 1xbet 후기efix="og: http://ogp.me/ns# fb: http://ogp.me/ns/fb# article: http://ogp.me/ns/article#"> 1xbet 후기
  1. HOME
  2. About Otsuka
  3. News Releases
  4. 2016
  5. U.S. FDA Ap1xbet 후기oves Labeling Update of REXULTI®(brexpi1xbet 후기azole) for Maintenance Treatment of Schizophrenia in Patients in the U.S.

Otsuka Pharmaceuti1xbet 후기l Co., Ltd.

Pharmaceuti1xbet 후기ls
September 26, 2016

U.S. FDA Ap1xbet 후기oves Labeling Update of REXULTI®(brexpi1xbet 후기azole) for Maintenance Treatment of Schizophrenia in Patients in the U.S.

  • Labeling update includes clinical data on use of REXULTI in adult patients with schizophrenia in t1xbet 후기 maintenance phase of treatment
  • Ap1xbet 후기oval was based on REXULTI demonstrating efficacy and safety in a long-term randomized withdrawal trial
  • T1xbet 후기 trial demonstrated a statistically significant (p < 0.0001) longer time to relapse in patients treated with REXULTI compared to placebo-treated patients

Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and H. Lundbeck A/S (Lundbeck) announced today that the U.S. Food and Drug Administration (FDA) ap1xbet 후기oved the labeling update of REXULTI® (brexpi1xbet 후기azole) to reflect clinical data for maintenance treatment of schizophrenia in patients in the U.S. The ap1xbet 후기oval was based on results from a long-term randomized withdrawal trial in adults with schizophrenia aged 18 to 65 years.

For additional information on t1xbet 후기 clinical trial results please refer to t1xbet 후기 announcement by OPDC 1xbet 후기re:

1xbet 후기evious
Next
Latest Pharmaceuti1xbet 후기l Business related News Releases
Most Recent Releases